Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor

Biochemical Pharmacology

Volumn 77, Issue 4, 2009, Pages 689-699

  Köhle, Christoph ^a   Bock, Karl Walter ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Ah receptor; Conjugate transporters; Cytochrome P450s; Drug metabolism; Pregnane X receptor; UDP glucuronosyltransferases

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BOSENTAN; CARBAMAZEPINE; CHOLESTEROL 7ALPHA MONOOXYGENASE; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 4A1; DRUG METABOLIZING ENZYME; EZETIMIBE; GLUCURONOSYLTRANSFERASE 1A1; HYPERFORIN; HYPERICUM PERFORATUM EXTRACT; MORPHINE; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; ORAL CONTRACEPTIVE AGENT; ORGANIC ANION TRANSPORTER 1; PREGNANE X RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RIFAMPICIN; THEOPHYLLINE; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ARTICLE; DRUG DEGRADATION; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; XENOBIOTIC METABOLISM;

CARRIER PROTEINS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; METABOLIC DETOXICATION, PHASE I; METABOLIC DETOXICATION, PHASE II; PHARMACEUTICAL PREPARATIONS; RECEPTOR CROSS-TALK; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; SUBSTRATE SPECIFICITY; TRANSCRIPTION FACTORS; XENOBIOTICS;

EID: 59149090185     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.05.020     Document Type: Article

References (98)

1. Gu Y.Z., Hogenesch J.B., and Bradfield C.A. The PAS superfamily: sensors of environmental and developmental signals. Annu Rev Pharmacol Toxicol 40 (2000) 519-561
2. Pascussi J.M., Gerbal-Chaloin S., Duret C., Daujat-Chavanieu M., Vilarem M.J., and Maurel P. The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences. Annu Rev Pharmacol Toxicol 48 (2008) 1-32
3. Xie W., and Evans R.M. Orphan nuclear receptors: the exotics of xenobiotics. J Biol Chem 276 (2001) 37739-37742
4. Maglich J.M., Stolz C.M., Goodwin B., Hawkins-Brown D., Moore J.T., and Kliewer S.A. Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 62 (2002) 638-646
5. Handschin C., and Meyer U.A. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch Biochem Biophys 433 (2005) 387-396
6. Eloranta J.J., Meier P.J., and Kullak-Ublick G.A. Coordinate transcriptional regulation of transport and metabolism. Methods Enzymol 400 (2005) 511-530
7. Tien E.S., and Negishi M. Nuclear receptors CAR and PXR in the regulation of hepatic metabolism. Xenobiotica 36 (2006) 1152-1163
8. Köhle C., and Bock K.W. Coordinate regulation of Phase I and II xenobiotic metabolism by the Ah receptor and Nrf2. Biochem Pharmacol 73 (2007) 1853-1862
9. Patel R.D., Hollingshead B.D., Omiecinski C.J., and Perdew G.H. Aryl hydrocarbon receptor activation regulates constitutive androstane levels in murine and human liver. Hepatology 46 (2007) 209-218
10. Conney A., Miller E.C., and Miller J.A. The metabolism of methylated amino azodyes. V. Evidence for induction of enzyme synthesis in the rat by 3-methylcholanthrene. Cancer Res 16 (1956) 450-459
11. Remmer H. Die Beschleunigung des Evipanabbaues unter der Wirkung von Barbituraten. Naturwissenschaften 8 (1958) 189
12. Remmer H., and Merker H.J. Drug-induced changes in the liver endoplasmic reticulum: association with drug-metabolizing enzymes. Science 142 (1963) 1657-1658
13. Tijet N., Boutros P.C., Moffat I.D., Okey A.B., Tuomisto J., and Pohjanvirta R. Aryl hydrocarbon receptor regulates distinct dioxin-dependent and dioxin-independent gene batteries. Mol Pharmacol 69 (2006) 140-153
14. Harper P.A., Riddick D.S., and Okey A.B. Regulating the regulator: factors that control levels and activity of the aryl hydrocarbon receptor. Biochem Pharmacol 72 (2006) 267-279
15. Xie W., Yeuh M.F., Radominska-Pandya A., Saini S.P.S., Negishi Y., Bottroff B.S., et al. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci USA 100 (2003) 4150-4155
16. Nebert D.W., and Gonzalez F.J. P450 genes: structure, evolution and regulation. Annu Rev Biochem (1987) 945-993
17. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6 (1996) 1-42
18. Nebert D.W., Dalton T.P., Okey A.B., and Gonzalez F.J. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 279 (2004) 23847-23850
19. Eaton D.L., Gallagher E.P., Bammler T.K., and Kunze K.L. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 5 (1995) 259-274
20. Ferguson S.S., LeCluyse E.L., Negishi M., and Goldstein J.A. Regulation of human CYP2C9 by the constitutive androstane receptor: discovery of a new distal binding site. Mol Pharmacol 62 (2002) 737-746
21. Gerbal-Chaloin S., Daujat M., Pascussi J.M., Pichard-Garcia L., Vilarem M.J., and Maurel P. Transcriptional regulation of CYP2C9 gene. J Biol Chem 277 (2002) 209-217
22. Shimada T., Yamazaki H., Mimura M., Inui Y., and Guengerich F.P. Interindividual variations in liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270 (1994) 414-423
23. Özdemir V., Kalow W., Tang B.K., Paterson A.D., Walker S.E., Endrenyi L., et al. Evaluation of the genetic component in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10 (2000) 373-388
24. Wojnowski L., Turner P.C., Pedersen B., Hustert E., Brockmöller J., Mendy M., et al. Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West Africa. Pharmacogenetics 14 (2004) 691-700
25. Mackenzie P.I., Bock K.W., Burchell B., Guillemette C., Ikushiro S., Iyanagi T., et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genom 15 (2005) 677-685
26. Tukey R.H., and Strassburg C.P. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40 (2000) 551-616
27. Burchell B., Lockley D.J., Staines A., Uesawa Y., and Coughtrie W.H. Substrate specificity of human hepatic UDP-glucuronosyltransferases. Methods Enzymol 400 (2005) 46-57
28. Gamage N., Barnett A., Hempel N., Duggleby R.G., Windmill K.F., Martin J.L., et al. Human sulfotransferases and their role in chemical metabolism. Toxicol Sci 90 (2006) 5-22
29. Hayes J.D., Flanagan J.U., and Jowsey I.R. Glutathione transferases. Annu Rev Pharmacol Toxicol 45 (2004) 51-88
30. Morel F., Rauch C., Coles B., Le Ferrec E., and Guillouzo A. The human glutathione transferase alpha locus: genomic organization of the gene cluster and functional characterization of the genetic polymorphism in the hGSTA1 promoter. Pharmacogenetics 12 (2002) 277-286
31. Eklund B.I., Moberg M., Bergquist J., and Mannervik B. Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Mol Pharmacol 70 (2006) 747-754
32. Ross D. Quinone reductases multitasking in the metabolic world. Drug Metab Rev 36 (2004) 639-654
33. Trauner M., and Boyer J.L. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 83 (2003) 633-671
34. Cui Y., König J., Leier I., Buchholz U., and Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276 (2001) 9626-9630
35. König J., Nies A.T., Cui Y., Leier I., and Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity and MRP2-mediated drug resistance. Biochim Biophys Acta 1461 (1999) 377-394
36. Keppler D. Uptake and efflux transporters for conjugates in human hepatocytes. Methods Enzymol 400 (2005) 531-542
37. Kopplow K., Letschert K., König J., Walter B., and Keppler D. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol 68 (2005) 1031-1038
38. Ballatori N., Christian W.V., Lee J.Y., Dawson P.A., Soroka C.J., Boyer J.L., et al. Ostα-Ostβ: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 42 (2005) 1270-1279
39. Geick A., Eichelbaum M., and Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampicin. J Biol Chem 276 (2001) 14581-14587
40. Ebert B., Seidel A., and Lampen A. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah receptor agonists. Carcinogenesis 26 (2005) 1754-1763
41. Blättler S.M., Rencurel F., Kaufmann M.R., and Meyer U.A. In the regulation of cytochrome P450 genes, phenobarbital targets LKB1 for necessary activation of AMP-activated protein kinase. Proc Natl Acad Sci USA 104 (2007) 1045-1050
42. Kress S., Reichert J., and Schwarz M. Functional analysis of the human cytochrome P450 (CYP1A1) gene enhancer. Eur J Biochem 258 (1998) 803-812
43. Ueda R., Iketaki H., Nagata K., Kimura S., Gonzalez F.J., Kusano K., et al. A common regulatory region functions bidirectionally in transcriptional activation of the human CYP1A1 and CYP1A2 genes. Mol Pharmacol 69 (2006) 1924-1930
44. Bertilsson G., Heidrich J., Svensson K., Asman M., Jendeberg L., Sydow-Backman M., et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 95 (1998) 12208-12213
45. Blumberg B., Sabbagh W., Juguilon H., Bolado J., van Meter C.M., Ong E.S., et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12 (1998) 3195-3205
46. Kliewer S.A., Moore J.T., Wade L., Staudinger J.L., Watson M.A., Jones S.A., et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92 (1998) 73-82
47. Aldridge T.C., Tugwood J.D., and Green S. Identification and characterization of DNA elements implicated in the regulation of CYP4A1 transcription. Biochem J 306 (1995) 473-479
48. Radjendirane V., and Jaiswal A.K. Antioxidant response element-mediated 2,3,7, 8-tetrachlorodibenzo-p-dioxin (TCDD) induction of human NADP(H):quinone oxidoreductase 1 gene expression. Biochem Pharmacol 58 (1999) 1649-1655
49. Morel F., Fardel O., Meyer D.J., Lanouet S., Gilmore K.S., Meunier B., et al. Preferential increase of glutathione S-transferase class alpha transcripts in cultured human hepatocytes by phenobarbital, 3-methylcholanthrene, and dithiolthiones. Cancer Res 53 (1993) 2231-2234
50. Yueh M.F., Huang Y.H., Hiller A., Chen S., Nguyen N., and Tukey R.H. Involvement of the xenobiotic response element (XRE) in Ah receptor-mediated induction of human UDP-glucuronosyltransferase 1A1. J Biol Chem 276 (2003) 15001-15006
51. Sugatani J., Sueyoshi T., Negishi M., and Miva M. Regulation of the human UGT1A1 gene by nuclear receptors constitutive active/androstane receptor, pregnane X receptor, and glucocorticoid receptor. Methods Enzymol 400 (2005) 92-104
52. Chen S., Beaton D., Nguyen N., Senekeo-Effenberger K., Brace-Sinnokrak E., Argikar U., et al. Tissue-specific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus. J Biol Chem 280 (2005) 3747-3757
53. Münzel P.A., Schmohl S., Buckler F., Jaehrling J., Raschko F.T., Köhle C., et al. Contribution of the Ah receptor to phenolic antioxidant-mediated expression of human and rat UDP-glucuronosyltransferase UGT1A6 in Caco-2 and rat hepatoma 5L cells. Biochem Pharmacol 66 (2003) 841-847
54. Barbier O., Villeneuve L., Bocher V., Fontaine C., Torra P.I., Duhem C., et al. The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor α and γ target gene. J Biol Chem 278 (2003) 13975-13983
55. Jigorel E., Le Vee M., Boursier-Neyret C., Parmentier Y., and Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Disp 34 (2006) 1756-1763
56. Kast H.R., Goodwin B., Tarr P.T., Jones S.A., Anisfeld A.M., Stolz C.M., et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277 (2002) 2908-2915
57. Hitzl M., Klein K., Zanger U.M., Nüssler A.K., Neuhaus P., et al. Influence of omeprazole on multidrug resistance protein 3 expression in human liver. J Pharmacol Exp Ther 304 (2003) 524-530
58. Takada T., Suzuki H., and Sugiyama Y. Characterization of the 5′-flanking region of human MRP3. Biochem Biophys Res Commun 270 (2000) 728-732
59. Savas U., Griffin K.J., and Johnson E.F. Molecular mechanisms of cytochrome P-450 induction by xenobiotics: an expanded role for nuclear hormone receptors. Mol Pharmacol 56 (1999) 851-857
60. Wang H., Faucette S., Sueyoshi T., Morre R., Ferguson S., Negishi M., et al. A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 278 (2003) 14146-14152
61. Goodwin B., Hodgson E., and Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56 (1999) 1329-1339
62. Yueh M.F., and Tukey R.H. Nrf2-Keap1 signaling pathway regulates human UGT1A1 expression in vitro and in transgenic UGT1 mice. J Biol Chem 282 (2007) 8749-8758
63. Senekeo-Effenberger K., Chen S., Brace-Sinnokrak E., Bonzo J.A., Yueh M.F., Argikar U., et al. Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor α activation. Drug Metab Disp 35 (2007) 419-427
64. Caspersen C.S., Reznik B., Weldy P.L., Abildskov K.M., Stark R.I., and Garland M. Molecular cloning of the baboon UDP-glucuronosyltransferase 1A gene family Evolution of the primate UGT1 locus and relevance for models of human drug metabolism. Pharmacogenet Genom 17 (2007) 11-24
65. Sugatani J., Nishitani S., Yamakawa K., Yoshinari K., Sueoshi T., Negishi M., et al. Transcriptional regulation of human UGT1A1 gene expression: activated glucocorticois receptor enhances constitutive androstane receptor/pregnane X receptor-mediated UDP-glucuronosyltransferase 1A1 regulation with glucocorticoid receptor interacting protein 1. Mol Pharmacol 67 (2005) 845-855
66. Sugatani J., Yamakawa K., Yoshinari K., Machida T., Takagi H., Mori M., et al. Identification of a defect in the UGT1A1 promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 292 (2002) 492-497
67. Gardner-Stephen D., Heydel J.M., Goyal A., Lu Y., Xie W., Lindblom T., et al. Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expresssion. Drug Metab Disp 32 (2004) 340-347
68. Gregory P.A., Lewinsky R.H., Gardner-Stephen, and Mackenzie P.I. Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol Appl Pharmacol 199 (2004) 354-363
69. Staudinger J.L., Goodwin B., Jones S.A., Hawkins-Brown D., MacKenzie K.I., Latour A., et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 98 (2001) 3369-3374
70. Xie W., Radominska-Pandya A., Shi Y., Simon C.M., Nelson M.C., Ong E.S., et al. An essential role for nuclear receptors SXR/PXR in detoxification of bile acids. Proc Natl Acad Sci USA 98 (2001) 3375-3380
71. Saini S.P.S., Sonoda J., Xu L., Toma D., Uppal H., Mu Y., et al. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol Pharmacol 65 (2004) 292-300
72. Wietholtz H., Marschall H.U., Sjövall J., and Matern S. Stimulation of bile acid 6-alpha-hydroxylation by rifampin. J Hepatol 24 (1996) 713-718
73. Hoensch H.P., Balzer K., Dylewicz P., Kirch W., Goebell H., and Ohnhaus E. Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur J Clin Pharmacol 28 (1985) 475-477
74. Denison M.S., and Nagy S.R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Ann Rev Pharmacol Toxicol 43 (2003) 309-334
75. Huang W., Ma K., Zhang J., Qatanani M., Cuvillier J., Liu J., et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 312 (2006) 233-236
76. Huang W., Zhang J., Chua S.S., Qatanani M., Han Y., Granata R., et al. Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc Natl Acad Sci USA 100 (2003) 4156-4161
77. Köhle C., Möhrle B., Münzel P.A., Schwab M., Wernet D., Badary O.A., et al. Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians. Biochem Pharmacol 65 (2003) 1521-1527
78. Kapitulnik J. Bilirubin: an endogenous product of heme degradation with both cytotoxic and cytoprotective properties. Mol Pharmacol 66 (2004) 773-779
79. Yoder Graber A.L., Ramirez J., Innocenti F., and Ratain M.J. UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Pharmacogenetics Genomics 17 (2007) 619-627
80. Köhle C., and Bock K.W. Activation of coupled Ah receptor and Nrf2 gene batteries by dietary phytochemicals in relation to chemoprevention. Biochem Pharmacol 72 (2006) 795-805
81. Smith C.M., Graham R.A., Krol W.l., Silver I.S., Negishi M., Wang H., et al. Differential UGT1A1 induction by chrysin in primary human hepatocytes and HepG2 cells. J Pharmacol Exp Ther 315 (2005) 1256-1264
82. Kensler T.W., Chen J.G., Egner P.A., Fahey J.W., Jacobson L.P., Stephenson K.K., et al. Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Quidong, People's Republic of China. Cancer Epidemiol Biomarkers Prev 14 (2005) 2605-2613
83. Nebert D., and Gelboin H.V. Substrate-inducible microsomal aryl hydroxylase in mammalian cell culture. J Biol Chem 243 (1968) 6242-6249
84. Conney A.H. Interaction of drug-metabolizing enzymes: a path to the discovery of multiple cytochromes P450. Annu Rev Pharmacol Toxicol 43 (2003) 1-30
85. Ruschitzka F., Meier P.J., Turina M., Luscher T.F., and Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet 355 (2000) 548-549
86. Fromm M.F., Dilger K., Busse D., Kroemer H.K., Eichelbaum M., and Klotz U. Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction. Br J Clin Pharmacol 45 (1998) 247-255
87. Oswald S., Haenisch S., Fricke C., Sudhop T., Remmler C., Giessmann T., et al. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharm Ther 79 (2006) 206-217
88. Fromm M.F., Eckhardt K., Li S., Schänzle G., Hofmann U., Mikus G., et al. Loss of analgesic effect of morphine due to coadministration of rifampicin. Pain 72 (1997) 261-267
89. Treiber A., Schneiter R., Häusler S., and Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as a common mechanism of its interactions with cyclosporine A, rifampicin, and sildenafil. Drug Metab Disp 35 (2007) 1400-1407
90. Oscarson M., Zanger U.M., Rifki O.K., Klein K., Eichelbaum M., and Meyer U.A. Transcriptional profiling of genes induced in livers of patients treated with carbamazepine. Clin Pharmacol Ther 80 (2006) 440-456
91. Wolbold R., Klein K., Burk O., Nüssler A.K., Neuhaus P., Eichelbaum M., et al. Sex as a major factor of CYP3A4 expression in human liver. Hepatology 38 (2003) 978-988
92. Saussele T., Burk O., Blievernicht J.K., Nussler A.Q., Nussler N., et al. Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. Clin Pharmacol Ther 82 (2007) 265-274
93. Buchthal J., Grund K.E., Buchmann A., Schrenk D., Beaune P., and Bock K.W. Induction of cytochrome P450A by smoking and omeprazole in comparison with UDP-glucuronosyltransferase in biopsies of human duodenal mucosa. Eur J Clin Pharmacol 47 (1995) 431-435
94. Gerbal-Chaloin S., Pichard-Garcia L., Fabre J.M., Sa-Cunha A., Poellinger L., Maurel P., et al. Role of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide. Cell Signal 18 (2006) 740-750
95. Bock K.W., Wiltfang J., Blume R., Ullrich D., and Bircher J. Paracetamol as a test drug to determine glucuronide formation in man Effects of inducers and of smoking. Eur J Clin Pharmacol 31 (1987) 677-683
96. Bock K.W., Schrenk D., Forster A., Griese E.U., Mörike K., Brockmeier D., et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4 (1994) 209-218
97. Soars M.G., Petullo D.M., Eckstein J.A., Kasper S.C., and Wrighton S.A. An assessment of UDP-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Disp 32 (2004) 140-148
98. Meier Y., Pauli-Magnus C., Zanger U.M., Klein K., Schaeffeler E., Nussler A.K., et al. Interindividual variability of canalicular ATP-binding cassette (ABC)-transporter expression in human liver. Hepatology 44 (2006) 62-74